Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Ltd. (SGX:BS6) has announced that it will be increasing its dividend from last year's comparable payment on the 13th of May to CN¥0.12. This will take the dividend yield to an attractive 5.6%, ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.